Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- ferritin krev MeSH
- lidé MeSH
- nádorové biomarkery krev MeSH
- nádory slinivky břišní krev mortalita patologie MeSH
- pilotní projekty MeSH
- prognóza MeSH
- ROC křivka MeSH
- staging nádorů MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- ferritin MeSH
- nádorové biomarkery MeSH
Prognosis of patients with pancreas cancer is very poor. The aim of the study was to test the significance of laboratory parameters in the prognosis of patients with pancreas cancer. The studied group included 57 patients (31 men, 26 women, mean age 65 ± 9 years). Blood was collected at the time of diagnosis of pancreas cancer and basic laboratory parameters, including nutritional and inflammatory markers and tumour markers were measured. Patients were followed up until death (median survival 147 days). Ferritin, iron, albumin, prealbumin, cholinesterase, haemoglobin, C-reactive protein, alkaline phosphatase and carcinoembryonic antigen were significant for patients' prognosis in univariate analysis while CA 19-9, bilirubin, liver, pancreas and kidney tests and lipids were not. Multivariate Cox regression demonstrated ferritin, iron and albumin as independent mortality predictors (RR (95%CI), per standard deviation: ferritin 1.497(1.215-2.241), p = 0.002; albumin, 0.716(0.521-0.977), p = 0.035; iron, 0.678(0.504-0.915), p = 0.010). Iron correlated significantly with albumin (r = 0.397, p = 0.002) but neither iron nor albumin correlated with ferritin. Patients who survived 100 days had significantly lower ferritin (median 239 μg/l vs. non-survivors 435 μg/l, p = 0.014), significantly higher albumin but the difference in serum iron was not quite significant. ROC analysis for ferritin revealed AUC for 100 days survival of 0.710, p = 0.007 (and 0.725, p = 0.004 for 200 days survival). AUC for albumin for 100 days survival was not significant (p = 0.073). This study points out ferritin as an independent mortality predictor in patients with pancreas cancer. High serum levels of ferritin at the time of diagnosis of pancreas cancer indicate bad prognosis of the patient.
Zobrazit více v PubMed
Ann Oncol. 2010 Mar;21(3):441-447 PubMed
Ann Surg. 2001 Dec;234(6):758-68 PubMed
Chemotherapy. 2010;56(6):501-6 PubMed
Med Oncol. 2010 Jun;27(2):268-77 PubMed
Eur J Nucl Med. 1981;6(7):331-6 PubMed
Oncology. 1984;41(6):393-5 PubMed
Pancreatology. 2005;5(6):576-90 PubMed
Digestion. 1982;25(4):258-62 PubMed
Hepatogastroenterology. 1985 Jun;32(3):146-8 PubMed
Int J Pancreatol. 1988;3 Suppl 1:S113-7 PubMed
Biomedicine. 1978 Jul-Aug;28(4):203-6 PubMed
Lancet Oncol. 2007 Sep;8(9):773-83 PubMed
Clin Cancer Res. 2005 May 1;11(9):3175-83 PubMed
Pancreas. 2006 Oct;33(3):240-5 PubMed
Am Surg. 2004 Mar;70(3):235-40; discussion 240 PubMed
Ann Clin Biochem. 1991 Jan;28 ( Pt 1):34-8 PubMed
Surgery. 2007 May;141(5):610-8 PubMed
Dig Surg. 2005;22(5):353-63 PubMed
Biochim Biophys Acta. 2010 Aug;1800(8):793-7 PubMed
Pancreas. 2010 Nov;39(8):1247-53 PubMed
